Man­u­fac­tur­ing roundup: Lon­za to man­u­fac­ture two new FDA-ap­proved ther­a­pies in Hous­ton; Ei­sai fin­ish­es project in Japan

Man­u­fac­tur­ing gi­ant Lon­za can add more FDA-ap­proved ther­a­pies to its reper­toire.

The com­pa­ny an­nounced that two ther­a­pies man­u­fac­tured at its Hous­ton site, Zyn­te­glo and Skysona, have net­ted com­mer­cial ap­proval in Q3 of this year. Both drugs are made by blue­bird bio and were ap­proved in Au­gust and Sep­tem­ber. This marks three cell and gene ther­a­pies that Lon­za makes in Hous­ton.

Lon­za’s cell and gene ther­a­py man­u­fac­tur­ing site in Hous­ton had passed pre-li­cens­ing in­spec­tion for vi­ral vec­tor man­u­fac­tur­ing and then even­tu­al man­u­fac­tur­ing of the cell ther­a­pies in 2021 and 2022 re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER